Document is current
Any future updates will be listed below
-
Authors
Ghanchi, Faruque https://orcid.org/0000-0002-4448-8162
Bourne, Rupert
Downes, Susan M.
Gale, Richard
Rennie, Christina https://orcid.org/0000-0001-9895-4758
Tapply, Ian
Sivaprasad, Sobha
-
Funding
Funding for this research was provided by:
Allergan
unrestricted grant for research and preparation of review
- License Information
-
More Information
Article History
Received: 20 July 2021
Revised: 19 August 2021
Accepted: 7 September 2021
First Online: 1 January 2022
Competing interests
: FG: Institutional research grants from: Allergan, Bayer, Boehringer Ingelheim, Chengdu Pharma, Clearside, Novartis, Roche. Travel Grants from Allergan, Bayer, Novartis. Lecture fees from: Allergan, Alimera, Heidelberg, Bayer, Novartis, Roche, Ad board/Consultancy for Allergan, Alimera, Apellis, Bayer, Boehringer Ingelheim, Novartis, Roche. Editorial board member for <i>Eye</i> at time of publication. RG: Consultancy for Novartis, Bayer, Roche, Alimera/Allergan, Santen, Research/Educational grants from Bayer, Novartis. CR: Travel grants from Novartis, Bayer, Allergan; Advisory board/consultancy for Allergan, Alimera, Novartis. RB<b>:</b> Consultancy for Santen, Allergan, Thea. Editorial board member for <i>Eye</i> at time of publication. SS<b>:</b> Research grants from Novartis, Bayer, Allergan, Roche, Boehringer Ingelheim, and Optos Plc, travel grants from Novartis and Bayer, speaker fees from Novartis, Bayer, and Optos Plc, and attending advisory board meetings for Novartis, Bayer, Allergan, Roche, Boehringer Ingelheim, Optos Plc, Oxurion, Opthea, Apellis, Oculis and Heidelberg Engineering. Editor in Chief of <i>Eye</i> at time of publication. SD: remunerated consultancies for Allergan, Janssen, Boehringer Ingelheim, and Circadian Therapeutics; travel grants/honoraria from Ely Lilly and Novartis, Bayer and is/has been a PI on pharma research clinical trials sponsored by Novartis, Bayer, Allergan, Roche. IT: None.
